Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06858839 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
A Phase 3 study of Obesity, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 3,853
- Enrollment target
- 20
- Study locations
NCT06858839: Active Phase 3 study of Obesity, sponsored by Amgen.
NCT06858839 is a Phase 3 study of Obesity that is active but no longer recruiting, run by Amgen. The registered enrollment target is 3,853 participants, above the 815-participant average among 1,053 other Obesity trials with a reported enrollment target (373% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06858839, a Phase 3 study of Obesity, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 3,853 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Maridebart Cafraglutide
Study Locations (20)
California
- Ark Clinical Research- Tustin - Fountain Valley
- Long Beach Clinical Trials Services Inc - Long Beach
- Ark Clinical Research- Long Beach - Long Beach
- Catalina Research Institute - Montclair
- Artemis Institute for Clinical Research - Riverside
- Artemis Institute for Clinical Research - San Diego
- Apex Clinical Research - San Diego
- Southern California Clinical Research - Santa Ana
- Diablo Clinical Research - Walnut Creek
Florida
- Indago Research and Health Center - Hialeah
- Jacksonville Center for Clinical Research - Jacksonville
- Clinical Neuroscience Solutions - Jacksonville - Jacksonville
- South Florida Wellness and Clinical Research Institute - Margate
- Optimus U Corporation - Miami
Alabama
- Pinnacle Research Group LLC - Anniston
- Alliance For Multispecialty Research - Daphne - Daphne
- Alliance for Multispecialty Research Mobile - Mobile
Connecticut
- Yale School of Medicine - New Haven
- Chase Medical Research LLC - Waterbury
Arizona
- Avacare Foothills Research Center - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,853 participants |
| Start Date | 2025-03-12 |
| Est. Completion | 2027-04-16 |
| Phase | Phase 3 |
What the registry record for NCT06858839 still lists
NCT06858839 is an interventional study that assigns participants to a tested intervention. Its 3,853 participants enrollment target places it among the larger protocols in the corpus, above the 815-participant average among 1,053 other Obesity trials with a reported enrollment target (373% higher).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06858839 names 20 study sites across 5 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06858839 about?
NCT06858839 is a clinical study titled "Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight". The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
What is the current status of trial NCT06858839?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 3,853 participants. The study started on 2025-03-12. Estimated completion is 2027-04-16.
What conditions does trial NCT06858839 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06858839?
The interventions under investigation include: Placebo (DRUG), Maridebart Cafraglutide (DRUG).
Who is sponsoring clinical trial NCT06858839?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06858839 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06858839's enrollment target sits among peer trials
3,853 26th of 1053 higher than 1,028 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07087613 · 3,850 participants
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
- NCT05919342 · 3,904 participants · NA
Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"
- NCT04573660 · 3,784 participants
Abbott Vascular Medical Device Registry
- NCT03936335 · 3,930 participants
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI